The cost of asthma treatment in Spain and rationalizing the expense

Journal of Investigational Allergology and Clinical Immunology

Volumn 11, Issue 3, 2001, Pages 139-148

  Nieto, Antonio ^a   Álvarez Cuesta, Emilio ^a   Boquete, Manuel ^a   Mazón, Ángel ^a   De la Torre, Fernando ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Allergy; Asthma; Costs; Immunotherapy; Spain

Indexed keywords

ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; IPRATROPIUM BROMIDE; KETOTIFEN; XANTHINE DERIVATIVE;

ALLERGY; ASTHMA; CORRELATION ANALYSIS; COST BENEFIT ANALYSIS; DISEASE COURSE; DRUG COST; ECONOMIC ASPECT; GENERAL PRACTICE; GEOGRAPHIC DISTRIBUTION; GEOGRAPHY; HUMAN; HYPOTHESIS; IMMUNOTHERAPY; INTERNAL MEDICINE; MEDICAL SPECIALIST; OUTCOMES RESEARCH; PEDIATRICS; PREVALENCE; REVIEW; SPAIN; UNITED STATES;

ANTI-ASTHMATIC AGENTS; ASTHMA; COSTS AND COST ANALYSIS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; SPAIN;

EID: 0035568949     PISSN: 10189068     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Epidemiology of asthma
2. Epidemiological trends in bronchial asthma
3. The costs of asthma
4. Farmacoeconomía: Evaluación económica de los medicamentos
5. Changing patterns of asthma hospitalization among children: 1979 to 1987
6. School functioning of US children with asthma
7. Managed care and the treatment of asthma
8. Bronchial asthma. A cost of illness analysis
9. Direct and indirect costs of asthma in Canada, 1990
10. An economic evaluation of asthma in the United States
11. Costs of rhinitis and asthma
12. The eternal triangle: Benefit, risk, and cost of therapeutic agents
13. Guidelines for the diagnosis and management of asthma
14. Allergen-specific treatment for asthma: III
15. Cellular events in the bronchi of mild asthma and after bronchial provocation
16. Allergen-induced increase in non-allergic bronchial reactivity
17. Rhinovirus upper respiratory infection increases airway reactivity in late asthmatic reactions
18. Indoor allergens and asthma: Report of the Third International Workshop
19. Atopic profile of inner-city asthma with a comparative analysis on the cockroach-sensitive and ragweed-sensitive subgroups
20. Characteristics of inner-city children with asthma. The National Cooperative inner-city asthma study
21. Allergy and Asthma. I. The dose relationship of allergy to severity of childhood asthma
22. Association of asthma with serum IgE levels and skin-test reactivity to allergens
23. Identification of T-lymphocytes, macrophages, and activated eosinophils in the bronchial mucosa of intrinsic asthma: Relationship to symptoms and bronchial responsiveness
24. High-affinity IgE receptor (FcεRI)-bearing cells in bronchial biopsies from atopic and non-atopic asthma
25. IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and non-atopic asthma: Evidence against "intrinsic" asthma being a distinct immunopathologic entity
26. Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and non-atopic subject with asthma
27. Molecular concepts of IgE-initiated inflammation in atopic and nonatopic asthma
28. Association of asthma with serum IgE levels and skin-test reactivity to allergens
29. Risk factors for developing wheezing and asthma in childhood
30. Specialty differences in the treatment of asthma
31. Results of a program to reduce admissions for adult asthma
32. Measuring the severity and outcomes of asthma care by generalists and allergists
33. Controlled trial of a home and ambulatory program for asthmatic children
34. Facilitated referral to asthma specialist reduces relapses in asthma emergency room visits
35. Establishment of an asthma program in a large maintenance organization
36. Allergist influence on asthma care
37. An intervention program to reduce cost of asthma care in patients who have required intubation
38. La prevención y los costes del asma. Un modelo para una asistencia sanitaria effectiva en relación al coste
39. Cost effectiveness of an allergy consultation in the management of asthma
40. Reduction in resource utilization by an Asthma Outreach Program
41. An asthma center: Outcomes validation
42. Asthma patients fare better under allergists care
43. Effectiveness of a specialized asthma clinic in reducing asthma morbidity in an inner-city population
44. A self-management program for adult asthma. Part II cost-benefit analysis
45. Speciality care for asthma is associated with greater use of inhaled corticosteroids & lower use of hospital and emergency service in a large managed care organization
46. Care of asthma: Allergy clinic versus emergency room
47. Effect of allergist/immunologist (A/I) consultation on hospital readmissions and follow-up care of asthma in an inner-city pediatric population
48. Is asthma curable?
49. The control of asthma in childhood, its value in the prevention of respiratory allergy in later life
50. Prognosis of bronchial asthma arising in infancy after nonspecific treatment hitherto applied
51. Asthma in children: A follow-up study in 689 patients after an interval of 20 years
52. The value of hyposensitization therapy for bronchial asthma in children: A 14-year study
53. Asma infantil en 1996
54. An intervention program to reduce the hospitalization cost of asthmatic patients requiting intubation
55. An economic evaluation of short-term inpatient rehabilitation for children with severe asthma
56. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials
57. Evolution of the late asthmatic reaction during immunotherapy and after stopping immunotherapy
58. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study
59. Bakers' asthma: Prevalence and evaluation of immunotherapy with a wheat flour extract
60. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids
61. Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract
62. Allergen-antibody complexes can efficiently prevent seasonal rhinitis and asthma in grass pollen hypersensitive patients. Allergen-antibody complex immunotherapy
63. Immunotherapy in asthma: An updated systematic review
64. WHO position paper. Allergen immunotherapy: Therapeutic vaccines for allergic diseases
65. Preventive allergy treatment (PAT)
66. Immunotherapy with partially purified and standardized tree pollen extract. IV. Results from long-term (6-year) follow-up
67. Therapie des allergischen asthmas. Die spezifische hyposensibilisierung kann helfen, kosten in milliardenhöhe einzusparen
68. Clinical and immunologic responses to immunotherapy
69. Monoclonal antibody-standardized cat extract immunotherapy: Risk-benefit effects from a double-blind placebo study
70. A double-blind study of the effectiveness and specificity of injection therapy in ragweed hay fever
71. Grass pollen immunotherapy: A single year double-blind placebo-controlled study in patients with grass pollen-induced asthma and rhinitis
72. The relationships between late cutaneous responses and specific antibody responses with the outcome of immunotherapy for seasonal allergic rhinitis
73. Seasonal asthma in northern California: Allergic causes and efficacy of immunotherapy
74. A controlled trial of immunotherapy for asthma in allergic children
75. Long-term clinical efficacy of grass-pollen immunotherapy